key: cord-0832956-stnz60vt
authors: nan
title: NICE COVID-19 rapid guidelines
date: 2021-05-01
journal: PharmacoEcon Outcomes News
DOI: 10.1007/s40274-021-7682-3
sha: 2742c8dee11990a915e287fb9ca1ba85f67f630a
doc_id: 832956
cord_uid: stnz60vt

nan

The rapid guidelines on skin conditions, and GI and liver conditions, treated with drugs that affect the immune response are intended to maximise the safety of children and adults whose disorders are treated with drugs affecting the immune response during the COVID-19 pandemic. Recommendations on treatment considerations for patients not known to have COVID-19 have been updated to take into account COVID-19 vaccination status.

The guidelines are intended for health and care practitioners, health and care staff who are planning and delivering services, and commissioners. They bring together existing national and international guidance and policies, and advice from specialists working in the National Health Service (NHS).

Topical treatments should be continued for skin disorders in patients with known or suspected COVID-19, and topical treatments should be considered for new-onset skin conditions in preference to initiating systemic treatments that affect the immune system. Patients with known or suspected COVID-19 should not suddenly discontinue oral corticosteroids, and they should continue treatment of skin conditions with chloroquine, hydroxychloroquine, dapsone, mepacrine and sulfasalazine. However, they should consider temporarily stopping all other immunosuppressants, biological therapies and monoclonal antibodies.

The rapid guideline on GI and liver conditions treated with drugs affecting the immune response notes that patients can continue taking aminosalicylates, as they do not affect the immune response. Healthcare professionals should be aware that worsening GI symptoms and deteriorating liver function could be associated with COVID-19, and that patients taking drugs that affect the immune response may experience atypical COVID-19 symptoms (such as no fever if they are on corticosteroids), and that patients with liver failure may be at higher risk of severe COVID-19 if they are receiving drugs that affect the immune response.

COVID-19 rapid guideline: managing COVID-19 Internet Document

NICE. COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response Internet Document : 9

NICE. COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response Internet Document : 9

Adis © 2021 Springer Nature Switzerland AG. All rights reserved